Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MEVAC EDS 76 is an inactivated monovalent veterinary vaccine developed by Middle East for Vaccines (MEVAC) to protect poultry against Egg Drop Syndrome (EDS). The vaccine contains inactivated Egg Drop Syndrome '76 virus (avian Atadenovirus) at a concentration of ≥ 8.5 log10 EID50 per dose. It is designed to induce a protective immune response in chickens, breeders, layers, and ducks, specifically preventing the production of soft-shelled and shell-less eggs caused by the virus. The vaccine is formulated as an emulsion that may separate during storage, requiring vigorous shaking before administration to pullets, typically starting from 2 weeks of age and before the onset of lay.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MEVAC EDS 76.